American Century Companies Inc. Purchases Shares of 29,446 Arcellx, Inc. (NASDAQ:ACLX)

American Century Companies Inc. purchased a new position in shares of Arcellx, Inc. (NASDAQ:ACLX - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 29,446 shares of the company's stock, valued at approximately $2,258,000. American Century Companies Inc. owned about 0.05% of Arcellx as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in ACLX. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Arcellx by 9.6% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,836 shares of the company's stock valued at $754,000 after purchasing an additional 858 shares during the last quarter. Lord Abbett & CO. LLC lifted its holdings in shares of Arcellx by 2.1% during the third quarter. Lord Abbett & CO. LLC now owns 891,848 shares of the company's stock worth $74,478,000 after purchasing an additional 18,004 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Arcellx by 4.3% during the third quarter. Geode Capital Management LLC now owns 974,967 shares of the company's stock worth $81,434,000 after purchasing an additional 39,781 shares during the period. Swiss National Bank grew its position in Arcellx by 0.8% in the 4th quarter. Swiss National Bank now owns 63,400 shares of the company's stock valued at $4,862,000 after buying an additional 500 shares during the last quarter. Finally, Avanza Fonder AB acquired a new position in Arcellx in the 4th quarter valued at $184,000. Institutional investors and hedge funds own 96.03% of the company's stock.

Insider Activity

In other Arcellx news, Director Kavita Patel sold 1,500 shares of the stock in a transaction dated Tuesday, January 14th. The shares were sold at an average price of $65.87, for a total value of $98,805.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Rami Elghandour sold 38,300 shares of Arcellx stock in a transaction that occurred on Wednesday, February 26th. The shares were sold at an average price of $62.02, for a total transaction of $2,375,366.00. Following the sale, the insider now owns 149,186 shares of the company's stock, valued at approximately $9,252,515.72. The trade was a 20.43 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 55,955 shares of company stock valued at $3,507,263 in the last three months. 6.24% of the stock is currently owned by company insiders.

Arcellx Price Performance

Shares of ACLX stock traded up $2.49 during mid-day trading on Friday, hitting $59.15. The stock had a trading volume of 731,572 shares, compared to its average volume of 557,060. The firm has a market cap of $3.25 billion, a PE ratio of -83.31 and a beta of 0.33. The company's 50-day simple moving average is $65.44 and its 200-day simple moving average is $75.96. Arcellx, Inc. has a fifty-two week low of $47.88 and a fifty-two week high of $107.37.

Arcellx (NASDAQ:ACLX - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.87) EPS for the quarter, missing analysts' consensus estimates of ($0.63) by ($0.24). Arcellx had a negative net margin of 25.94% and a negative return on equity of 8.28%. The firm had revenue of $15.27 million during the quarter, compared to analyst estimates of $27.42 million. On average, analysts expect that Arcellx, Inc. will post -1.58 EPS for the current year.

About Arcellx

Arcellx, Inc, together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM).